SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Bio Key International Inc. – ‘10-Q’ for 9/30/23

On:  Monday, 11/20/23, at 5:06pm ET   ·   For:  9/30/23   ·   Accession #:  1437749-23-32644   ·   File #:  1-13463

Previous ‘10-Q’:  ‘10-Q’ on 8/18/23 for 6/30/23   ·   Latest ‘10-Q’:  This Filing   ·   2 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/20/23  Bio Key International Inc.        10-Q        9/30/23   62:5M                                     RDG Filings/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.18M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     24K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     24K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     20K 
11: R1          Document And Entity Information                     HTML     71K 
12: R2          Condensed Consolidated Balance Sheets (Current      HTML    147K 
                Period Unaudited)                                                
13: R3          Condensed Consolidated Balance Sheets (Current      HTML     27K 
                Period Unaudited) (Parentheticals)                               
14: R4          Condensed Consolidated Statements of Operations     HTML    115K 
                and Comprehensive Loss (Unaudited)                               
15: R5          Condensed Consolidated Statements of Stockholders'  HTML    114K 
                Equity (Unaudited)                                               
16: R6          Condensed Consolidated Statements of Cash Flows     HTML    139K 
                (Unaudited)                                                      
17: R7          Condensed Consolidated Statements of Cash Flows     HTML     19K 
                (Unaudited) (Parentheticals)                                     
18: R8          Note 1 - Nature of Business and Basis of            HTML     32K 
                Presentation                                                     
19: R9          Note 2 - Going Concern                              HTML     24K 
20: R10         Note 3 - Revenue From Contracts With Customers      HTML     83K 
21: R11         Note 4 - Accounts Receivable                        HTML     28K 
22: R12         Note 5 - Share Based Compensation                   HTML     33K 
23: R13         Note 6 - Inventory                                  HTML     28K 
24: R14         Note 7 - Commitments and Contingencies              HTML     25K 
25: R15         Note 8 - Leases                                     HTML     45K 
26: R16         Note 9 - Convertible Note Payable                   HTML     30K 
27: R17         Note 10 - Earnings (Loss) Per Share - Common Stock  HTML     32K 
                ("Eps")                                                          
28: R18         Note 11 - Stockholders' Equity                      HTML     34K 
29: R19         Note 12 - Fair Values of Financial Instruments      HTML     23K 
30: R20         Note 13 - Fair Value Measurement of Convertible     HTML     41K 
                Note Payable                                                     
31: R21         Note 14 - Major Customers and Accounts Receivables  HTML     22K 
32: R22         Note 15 - Income Taxes                              HTML     26K 
33: R23         Note 16 - Subsequent Events                         HTML     24K 
34: R24         Significant Accounting Policies (Policies)          HTML     33K 
35: R25         Note 3 - Revenue From Contracts With Customers      HTML     76K 
                (Tables)                                                         
36: R26         Note 4 - Accounts Receivable (Tables)               HTML     26K 
37: R27         Note 5 - Share Based Compensation (Tables)          HTML     31K 
38: R28         Note 6 - Inventory (Tables)                         HTML     27K 
39: R29         Note 8 - Leases (Tables)                            HTML     43K 
40: R30         Note 10 - Earnings (Loss) Per Share - Common Stock  HTML     30K 
                ("Eps") (Tables)                                                 
41: R31         Note 13 - Fair Value Measurement of Convertible     HTML     38K 
                Note Payable (Tables)                                            
42: R32         Note 3 - Revenue From Contracts With Customers      HTML     28K 
                (Details Textual)                                                
43: R33         Note 3 - Revenue From Contracts With Customers -    HTML     47K 
                Disaggregation of Revenue (Details)                              
44: R34         Note 4 - Accounts Receivable - Summary of Accounts  HTML     25K 
                Receivable (Details)                                             
45: R35         Note 5 - Share Based Compensation - Expenses for    HTML     23K 
                Continuing Operations (Details)                                  
46: R36         Note 6 - Inventory (Details Textual)                HTML     20K 
47: R37         Note 6 - Inventory - Components of Inventory        HTML     26K 
                (Details)                                                        
48: R38         Note 8 - Leases - Operating Lease Balance Sheet     HTML     48K 
                Information (Details)                                            
49: R39         Note 9 - Convertible Note Payable (Details          HTML     52K 
                Textual)                                                         
50: R40         Note 10 - Earnings (Loss) Per Share - Common Stock  HTML     26K 
                ("EPS") - Securities Excluded From the Diluted Per               
                Share Calculation (Details)                                      
51: R41         Note 11 - Stockholders' Equity (Details Textual)    HTML     80K 
52: R42         Note 13 - Fair Value Measurement of Convertible     HTML     36K 
                Note Payable (Details Textual)                                   
53: R43         Note 13 - Fair Value Measurement of Convertable     HTML     26K 
                Note Payable - Fair Value Measured On Recurring                  
                and Nonrecurring Basis (Details)                                 
54: R44         Note 13 - Fair Value Measurement of Convertable     HTML     27K 
                Note Payable - Unobsesrvable Input Reconciliation                
                (Details)                                                        
55: R45         Note 14 - Major Customers and Accounts Receivables  HTML     33K 
                (Details Textual)                                                
56: R46         Note 15 - Income Taxes (Details Textual)            HTML     32K 
57: R47         Note 16 - Subsequent Events (Details Textual)       HTML     49K 
60: XML         IDEA XML File -- Filing Summary                      XML    109K 
58: XML         XBRL Instance -- bkyi20230930_10q_htm                XML   1.24M 
59: EXCEL       IDEA Workbook of Financial Report Info              XLSX     87K 
 7: EX-101.CAL  XBRL Calculations -- bkyi-20230930_cal               XML    128K 
 8: EX-101.DEF  XBRL Definitions -- bkyi-20230930_def                XML    891K 
 9: EX-101.LAB  XBRL Labels -- bkyi-20230930_lab                     XML    696K 
10: EX-101.PRE  XBRL Presentations -- bkyi-20230930_pre              XML    910K 
 6: EX-101.SCH  XBRL Schema -- bkyi-20230930                         XSD    129K 
61: JSON        XBRL Instance as JSON Data -- MetaLinks              338±   530K 
62: ZIP         XBRL Zipped Folder -- 0001437749-23-032644-xbrl      Zip    191K 


‘10-Q’   —   Quarterly Report

Document Table of Contents

Page (sequential)   (alphabetic) Top
 
11st Page  –  Filing Submission
"Table of Contents
"Item 1- Financial Statements
"Condensed Consolidated Balance Sheets as of September 30, 2023 (unaudited) and December 31, 2022
"Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022 (Unaudited)
"Unaudited
"Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2023 and 2022
"Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 (Unaudited)
"Notes to Condensed Consolidated Financial Statements
"Item 2-Management's Discussion and Analysis of Financial Conditions and Results of Operations
"Item 4-Controls and Procedures
"Item 6-Exhibits
"Signatures

This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C: 
 i 0001019034  i BIO KEY INTERNATIONAL INC  i false  i --12-31  i Q3  i 2023  i   i   i 170,000,000  i 170,000,000  i 9,501,669  i 9,501,669  i 9,190,504  i 9,190,504  i 0.0001  i 0.0001  i 729,905  i -  i 371,956  i 918,260  i 83,333  i 9,895  i 1,373,549  i 34,145  i 63,973  i 2,200,000  i 3  i 0  i 0  i 0  i 0  i 0  i 0  i 0  i 0  i 2,200,000  i 18  i 30  i 50  i 1  i 1  i 3  i 1  i 0  i 0  i 0  i 0.175  i 5 EMESA – Europe, Middle East, South America 00010190342023-01-012023-09-30 xbrli:shares 00010190342023-11-17 thunderdome:item iso4217:USD 00010190342023-09-30 00010190342022-12-31 iso4217:USDxbrli:shares 0001019034us-gaap:ServiceMember2023-07-012023-09-30 0001019034us-gaap:ServiceMember2022-07-012022-09-30 0001019034us-gaap:ServiceMember2023-01-012023-09-30 0001019034us-gaap:ServiceMember2022-01-012022-09-30 0001019034us-gaap:LicenseMember2023-07-012023-09-30 0001019034us-gaap:LicenseMember2022-07-012022-09-30 0001019034us-gaap:LicenseMember2023-01-012023-09-30 0001019034us-gaap:LicenseMember2022-01-012022-09-30 0001019034bkyi:HardwareMember2023-07-012023-09-30 0001019034bkyi:HardwareMember2022-07-012022-09-30 0001019034bkyi:HardwareMember2023-01-012023-09-30 0001019034bkyi:HardwareMember2022-01-012022-09-30 00010190342023-07-012023-09-30 00010190342022-07-012022-09-30 00010190342022-01-012022-09-30 0001019034us-gaap:CommonStockMember2022-12-31 0001019034us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0001019034us-gaap:RetainedEarningsMember2022-12-31 0001019034us-gaap:CommonStockMember2023-01-012023-03-31 0001019034us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-31 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-31 0001019034us-gaap:RetainedEarningsMember2023-01-012023-03-31 00010190342023-01-012023-03-31 0001019034us-gaap:CommonStockMember2023-03-31 0001019034us-gaap:AdditionalPaidInCapitalMember2023-03-31 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-31 0001019034us-gaap:RetainedEarningsMember2023-03-31 00010190342023-03-31 0001019034us-gaap:CommonStockMember2023-04-012023-06-30 0001019034us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-30 0001019034us-gaap:RetainedEarningsMember2023-04-012023-06-30 00010190342023-04-012023-06-30 0001019034us-gaap:CommonStockMember2023-06-30 0001019034us-gaap:AdditionalPaidInCapitalMember2023-06-30 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-30 0001019034us-gaap:RetainedEarningsMember2023-06-30 00010190342023-06-30 0001019034us-gaap:CommonStockMember2023-07-012023-09-30 0001019034us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-30 0001019034us-gaap:RetainedEarningsMember2023-07-012023-09-30 0001019034us-gaap:CommonStockMember2023-09-30 0001019034us-gaap:AdditionalPaidInCapitalMember2023-09-30 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-30 0001019034us-gaap:RetainedEarningsMember2023-09-30 0001019034us-gaap:CommonStockMember2021-12-31 0001019034us-gaap:AdditionalPaidInCapitalMember2021-12-31 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 0001019034us-gaap:RetainedEarningsMember2021-12-31 00010190342021-12-31 0001019034us-gaap:CommonStockMember2022-01-012022-03-31 0001019034us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-31 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-31 0001019034us-gaap:RetainedEarningsMember2022-01-012022-03-31 00010190342022-01-012022-03-31 0001019034us-gaap:CommonStockMember2022-03-31 0001019034us-gaap:AdditionalPaidInCapitalMember2022-03-31 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-31 0001019034us-gaap:RetainedEarningsMember2022-03-31 00010190342022-03-31 0001019034us-gaap:CommonStockMember2022-04-012022-06-30 0001019034us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-30 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-30 0001019034us-gaap:RetainedEarningsMember2022-04-012022-06-30 00010190342022-04-012022-06-30 0001019034us-gaap:CommonStockMember2022-06-30 0001019034us-gaap:AdditionalPaidInCapitalMember2022-06-30 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-30 0001019034us-gaap:RetainedEarningsMember2022-06-30 00010190342022-06-30 0001019034us-gaap:CommonStockMember2022-07-012022-09-30 0001019034us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-30 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-30 0001019034us-gaap:RetainedEarningsMember2022-07-012022-09-30 0001019034us-gaap:CommonStockMember2022-09-30 0001019034us-gaap:AdditionalPaidInCapitalMember2022-09-30 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-30 0001019034us-gaap:RetainedEarningsMember2022-09-30 00010190342022-09-30 0001019034bkyi:SwivelSecureEuropeMember2023-01-012023-09-30 0001019034bkyi:SwivelSecureEuropeMember2022-01-012022-09-30 0001019034us-gaap:ServiceMembersrt:NorthAmericaMember2023-07-012023-09-30 0001019034us-gaap:ServiceMembersrt:SouthAmericaMember2023-07-012023-09-30 0001019034us-gaap:ServiceMemberbkyi:EMESAMember2023-07-012023-09-30 0001019034us-gaap:ServiceMembersrt:AsiaMember2023-07-012023-09-30 0001019034us-gaap:LicenseMembersrt:NorthAmericaMember2023-07-012023-09-30 0001019034us-gaap:LicenseMembersrt:SouthAmericaMember2023-07-012023-09-30 0001019034us-gaap:LicenseMemberbkyi:EMESAMember2023-07-012023-09-30 0001019034us-gaap:LicenseMembersrt:AsiaMember2023-07-012023-09-30 0001019034bkyi:HardwareMembersrt:NorthAmericaMember2023-07-012023-09-30 0001019034bkyi:HardwareMembersrt:SouthAmericaMember2023-07-012023-09-30 0001019034bkyi:HardwareMemberbkyi:EMESAMember2023-07-012023-09-30 0001019034bkyi:HardwareMembersrt:AsiaMember2023-07-012023-09-30 0001019034srt:NorthAmericaMember2023-07-012023-09-30 0001019034srt:SouthAmericaMember2023-07-012023-09-30 0001019034bkyi:EMESAMember2023-07-012023-09-30 0001019034srt:AsiaMember2023-07-012023-09-30 0001019034us-gaap:ServiceMembersrt:NorthAmericaMember2022-07-012022-09-30 0001019034us-gaap:ServiceMembersrt:SouthAmericaMember2022-07-012022-09-30 0001019034us-gaap:ServiceMemberbkyi:EMESAMember2022-07-012022-09-30 0001019034us-gaap:ServiceMembersrt:AsiaMember2022-07-012022-09-30 0001019034us-gaap:LicenseMembersrt:NorthAmericaMember2022-07-012022-09-30 0001019034us-gaap:LicenseMembersrt:SouthAmericaMember2022-07-012022-09-30 0001019034us-gaap:LicenseMemberbkyi:EMESAMember2022-07-012022-09-30 0001019034us-gaap:LicenseMembersrt:AsiaMember2022-07-012022-09-30 0001019034bkyi:HardwareMembersrt:NorthAmericaMember2022-07-012022-09-30 0001019034bkyi:HardwareMembersrt:SouthAmericaMember2022-07-012022-09-30 0001019034bkyi:HardwareMemberbkyi:EMESAMember2022-07-012022-09-30 0001019034bkyi:HardwareMembersrt:AsiaMember2022-07-012022-09-30 0001019034srt:NorthAmericaMember2022-07-012022-09-30 0001019034srt:SouthAmericaMember2022-07-012022-09-30 0001019034bkyi:EMESAMember2022-07-012022-09-30 0001019034srt:AsiaMember2022-07-012022-09-30 0001019034us-gaap:ServiceMembersrt:NorthAmericaMember2023-01-012023-09-30 0001019034us-gaap:ServiceMembersrt:SouthAmericaMember2023-01-012023-09-30 0001019034us-gaap:ServiceMemberbkyi:EMESAMember2023-01-012023-09-30 0001019034us-gaap:ServiceMembersrt:AsiaMember2023-01-012023-09-30 0001019034us-gaap:LicenseMembersrt:NorthAmericaMember2023-01-012023-09-30 0001019034us-gaap:LicenseMembersrt:SouthAmericaMember2023-01-012023-09-30 0001019034us-gaap:LicenseMemberbkyi:EMESAMember2023-01-012023-09-30 0001019034us-gaap:LicenseMembersrt:AsiaMember2023-01-012023-09-30 0001019034bkyi:HardwareMembersrt:NorthAmericaMember2023-01-012023-09-30 0001019034bkyi:HardwareMembersrt:SouthAmericaMember2023-01-012023-09-30 0001019034bkyi:HardwareMemberbkyi:EMESAMember2023-01-012023-09-30 0001019034bkyi:HardwareMembersrt:AsiaMember2023-01-012023-09-30 0001019034srt:NorthAmericaMember2023-01-012023-09-30 0001019034srt:SouthAmericaMember2023-01-012023-09-30 0001019034bkyi:EMESAMember2023-01-012023-09-30 0001019034srt:AsiaMember2023-01-012023-09-30 0001019034us-gaap:ServiceMembersrt:NorthAmericaMember2022-01-012022-09-30 0001019034us-gaap:ServiceMembersrt:SouthAmericaMember2022-01-012022-09-30 0001019034us-gaap:ServiceMemberbkyi:EMESAMember2022-01-012022-09-30 0001019034us-gaap:ServiceMembersrt:AsiaMember2022-01-012022-09-30 0001019034us-gaap:LicenseMembersrt:NorthAmericaMember2022-01-012022-09-30 0001019034us-gaap:LicenseMembersrt:SouthAmericaMember2022-01-012022-09-30 0001019034us-gaap:LicenseMemberbkyi:EMESAMember2022-01-012022-09-30 0001019034us-gaap:LicenseMembersrt:AsiaMember2022-01-012022-09-30 0001019034bkyi:HardwareMembersrt:NorthAmericaMember2022-01-012022-09-30 0001019034bkyi:HardwareMembersrt:SouthAmericaMember2022-01-012022-09-30 0001019034bkyi:HardwareMemberbkyi:EMESAMember2022-01-012022-09-30 0001019034bkyi:HardwareMembersrt:AsiaMember2022-01-012022-09-30 0001019034srt:NorthAmericaMember2022-01-012022-09-30 0001019034srt:SouthAmericaMember2022-01-012022-09-30 0001019034bkyi:EMESAMember2022-01-012022-09-30 0001019034srt:AsiaMember2022-01-012022-09-30 utr:M 0001019034srt:MinimumMember2023-09-30 0001019034srt:MaximumMember2023-09-30 0001019034us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-30 0001019034us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-30 0001019034us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-30 0001019034us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-30 0001019034us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-30 0001019034us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-30 0001019034us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-30 0001019034us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-30 0001019034country:NG2023-09-30 0001019034bkyi:ApproximationMember2023-09-30 0001019034bkyi:ApproximationMember2022-09-30 utr:Y xbrli:pure 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2022-12-22 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2022-12-222022-12-22 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2023-09-30 0001019034bkyi:WarrantsIssuedInConnectionWithNoteMember2022-12-222022-12-22 0001019034bkyi:WarrantsIssuedInConnectionWithNoteMember2022-12-22 0001019034bkyi:TheNoteMember2023-09-30 0001019034bkyi:TheNoteMember2022-12-31 0001019034us-gaap:EmployeeStockOptionMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2023-07-012023-09-30 0001019034us-gaap:EmployeeStockOptionMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2022-07-012022-09-30 0001019034us-gaap:EmployeeStockOptionMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2023-01-012023-09-30 0001019034us-gaap:EmployeeStockOptionMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2022-01-012022-09-30 0001019034us-gaap:WarrantMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2023-07-012023-09-30 0001019034us-gaap:WarrantMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2022-07-012022-09-30 0001019034us-gaap:WarrantMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2023-01-012023-09-30 0001019034us-gaap:WarrantMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2022-01-012022-09-30 0001019034bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2023-07-012023-09-30 0001019034bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2022-07-012022-09-30 0001019034bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2023-01-012023-09-30 0001019034bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2022-01-012022-09-30 0001019034bkyi:EmployeeStockPurchasePlanMember2021-06-18 0001019034bkyi:EmployeeStockPurchasePlanMember2021-06-182021-06-18 0001019034bkyi:EmployeeStockPurchasePlanMember2023-01-302023-09-30 0001019034bkyi:EmployeeStockPurchasePlanMember2022-01-302022-09-30 0001019034bkyi:SwivelSecureEuropeMember2022-03-082022-03-08 0001019034bkyi:SwivelSecureEuropeMember2022-03-08 0001019034us-gaap:RestrictedStockMember2022-01-012022-09-30 0001019034us-gaap:RestrictedStockMember2023-01-012023-09-30 0001019034us-gaap:RestrictedStockMember2023-07-012023-09-30 0001019034us-gaap:RestrictedStockMember2022-07-012022-09-30 0001019034us-gaap:CommonStockMembersrt:DirectorMember2023-07-012023-09-30 0001019034us-gaap:CommonStockMembersrt:DirectorMember2022-07-012022-09-30 0001019034us-gaap:CommonStockMembersrt:DirectorMember2023-01-012023-09-30 0001019034us-gaap:CommonStockMembersrt:DirectorMember2022-01-012022-09-30 0001019034bkyi:TheNoteMemberus-gaap:FairValueInputsLevel1Memberbkyi:SeniorSecuredPromissoryNoteMember2023-09-30 0001019034bkyi:TheNoteMemberus-gaap:FairValueInputsLevel2Memberbkyi:SeniorSecuredPromissoryNoteMember2023-09-30 0001019034bkyi:TheNoteMemberus-gaap:FairValueInputsLevel3Memberbkyi:SeniorSecuredPromissoryNoteMember2023-09-30 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2022-12-31 0001019034bkyi:TheNoteMemberus-gaap:FairValueInputsLevel1Memberbkyi:SeniorSecuredPromissoryNoteMember2022-12-31 0001019034bkyi:TheNoteMemberus-gaap:FairValueInputsLevel2Memberbkyi:SeniorSecuredPromissoryNoteMember2022-12-31 0001019034bkyi:TheNoteMemberus-gaap:FairValueInputsLevel3Memberbkyi:SeniorSecuredPromissoryNoteMember2022-12-31 0001019034bkyi:TheNoteMembersrt:WeightedAverageMemberbkyi:SeniorSecuredPromissoryNoteMember2023-09-30 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2023-01-012023-09-30 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2022-01-012022-12-31 0001019034bkyi:TheNoteMemberus-gaap:MeasurementInputDiscountRateMemberbkyi:SeniorSecuredPromissoryNoteMember2023-09-30 0001019034bkyi:TheNoteMemberus-gaap:MeasurementInputDiscountRateMemberbkyi:SeniorSecuredPromissoryNoteMember2022-12-31 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2023-01-012023-03-31 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2023-03-31 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2023-04-012023-06-30 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2023-06-30 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2023-07-012023-09-30 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-30 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberbkyi:TwoCustomersMember2023-07-012023-09-30 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-30 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberbkyi:OneCustomerMember2022-07-012022-09-30 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberbkyi:TwoCustomersMember2023-01-012023-09-30 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-30 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberbkyi:OneCustomerMember2022-01-012022-09-30 0001019034us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberbkyi:OneCustomerMember2023-01-012023-09-30 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberbkyi:ThreeCustomersMember2023-01-012023-09-30 0001019034us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberbkyi:OneCustomerMember2022-01-012022-12-31 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberbkyi:OneCustomerMember2022-01-012022-12-31 0001019034bkyi:UnitedStatesHongKongAndNigeriaMember2023-07-012023-09-30 0001019034bkyi:UnitedStatesHongKongAndNigeriaMember2023-01-012023-09-30 0001019034bkyi:UnitedStatesHongKongAndNigeriaMember2022-07-012022-09-30 0001019034bkyi:UnitedStatesHongKongAndNigeriaMember2022-01-012022-09-30 0001019034country:ES2023-01-012023-09-30 0001019034us-gaap:SubsequentEventMemberbkyi:PublicOfferingMember2023-10-302023-10-30 0001019034us-gaap:SubsequentEventMemberbkyi:PublicOfferingMember2023-10-30 0001019034bkyi:PrefundedWarrantsMemberus-gaap:SubsequentEventMember2023-10-302023-10-30 0001019034bkyi:CommonWarrantsMemberus-gaap:SubsequentEventMember2023-10-302023-10-30 0001019034bkyi:CommonWarrantsMemberus-gaap:SubsequentEventMember2023-10-30 0001019034bkyi:PrefundedWarrantsMemberus-gaap:SubsequentEventMember2023-10-30 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMemberus-gaap:SubsequentEventMember2023-10-302023-10-30
 

 

Table of Contents

 

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM  i 10-Q

 

 

 i 

QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended  i September 30, 2023

or

 

 i 

TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT

 

For the Transition Period from              to

 

Commission file number  i 1-13463

 

BIO-KEY INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 i Delaware

 i 41-1741861

(State or Other Jurisdiction of Incorporation of Organization)

(IRS Employer Identification Number)

 

 i 101 CRAWFORDS CORNER ROAD, SUITE 4116,  i HOLMDEL,  i NJ  i 07733

 

(Address of Principal Executive Offices)

 

( i 732)  i 359-1100

(Registrant’s telephone number, including area code)

 

Securities registered pursuance to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of each exchange on which

registered

   

 i Common Stock, par value $0.0001 per share

 i BKYI

 i Nasdaq Capital Market

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   i Yes  ☒   No  ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   i Yes ☒   No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

 

Accelerated filer ☐
  

 i Non-accelerated filer ☒

 

Smaller Reporting Company  i 
  
 

 

Emerging growth company   i 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined by rule 12b-2 of the Exchange Act)  Yes   i   No  ☒

 

Number of shares of Common Stock, $.0001 par value per share, outstanding as of November 17, 2023, is  i 13,731,669

 

 

 

 

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES

 

INDEX

 

PART I. FINANCIAL INFORMATION

 
   

Item 1— Financial Statements:

 

Condensed Consolidated Balance Sheets as of September 30, 2023 (unaudited) and December 31, 2022

3

Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022 (Unaudited)

4

Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2023 and 2022 (Unaudited)

5

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 (Unaudited)

7

Notes to Condensed Consolidated Financial Statements

9

   

Item 2—Management’s Discussion and Analysis of Financial Conditions and Results of Operations.

17

   

Item 4—Controls and Procedures.

24

   

PART II. OTHER INFORMATION

 
   

Item 6—Exhibits.

25

   

Signatures

26

 

 

 

 

 

PART I -- FINANCIAL INFORMATION

 

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

  

September 30,

  

December 31,

 
  

2023

  

2022

 
  

(Unaudited)

     

ASSETS

        

Cash and cash equivalents

 $ i 307,086  $ i 2,635,522 

Accounts receivable, net

   i 2,799,218    i 1,522,784 

Due from factor

   i 62,572    i 49,500 

Inventory

   i 4,289,213    i 4,434,369 

Prepaid expenses and other

   i 362,250    i 342,706 

Total current assets

   i 7,820,339    i 8,984,881 

Equipment and leasehold improvements, net

   i 69,202    i 107,413 

Capitalized contract costs, net

   i 264,348    i 283,069 

Deposits and other assets

   i -    i 8,712 

Deferred offering costs

   i 25,434    i - 

Operating lease right-of-use assets

   i 50,465    i 197,355 

Intangible assets, net

   i 1,519,592    i 1,762,825 

Total non-current assets

   i 1,929,041    i 2,359,374 

TOTAL ASSETS

 $ i 9,749,380  $ i 11,344,255 
         

LIABILITIES

        

Accounts payable

 $ i 1,656,107  $ i 1,108,279 

Accrued liabilities

   i 1,080,032    i 1,009,123 

Income taxes payable

   i 162,811    i - 

Convertible note payable

   i 2,331,497    i 2,596,203 

Government loan – BBVA Bank, current portion

   i 135,308    i 120,000 

Deferred revenue, current

   i 610,451    i 462,418 

Operating lease liabilities, current portion

   i 51,746    i 159,665 

Total current liabilities

   i 6,027,952    i 5,455,688 

Deferred revenue, long term

   i 32,354    i 52,134 

Deferred tax liability

   i 152,998    i 170,281 

Government loan – BBVA Bank – net of current portion

   i 221,625    i 326,767 

Operating lease liabilities, net of current portion

   i -    i 37,829 

Total non-current liabilities

   i 406,977    i 587,011 

TOTAL LIABILITIES

   i 6,434,929    i 6,042,699 
         

Commitments and Contingencies

          
         

STOCKHOLDERS’ EQUITY

        
         

Common stock — authorized, 170,000,000 shares; issued and outstanding; 9,501,669 and 9,190,504 of $.0001 par value at September 30, 2023 and December 31, 2022, respectively

   i 950    i 919 

Additional paid-in capital

   i 122,263,106    i 122,028,612 

Accumulated other comprehensive loss

  ( i 115,208)  ( i 242,602)

Accumulated deficit

  ( i 118,834,397)  ( i 116,485,373)

TOTAL STOCKHOLDERS’ EQUITY

   i 3,314,451    i 5,301,556 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 $ i 9,749,380  $ i 11,344,255 

 

See accompanying notes to the condensed consolidated financial statements.

 

3

 

 

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30,

   

September 30,

 
   

2023

   

2022

   

2023

   

2022

 

Revenues

                               

Services

  $  i 587,893     $  i 371,956     $  i 1,740,880     $  i 1,202,866  

License fees

     i 950,015        i 918,260        i 4,664,341        i 3,540,592  

Hardware

     i 279,200        i 83,333        i 424,583        i 518,377  

Total revenues

     i 1,817,108        i 1,373,549        i 6,829,804        i 5,261,835  

Costs and other expenses

                               

Cost of services

     i 125,039        i 162,632        i 639,996        i 554,222  

Cost of license fees

     i 203,891        i 173,310        i 1,022,919        i 604,677  

Cost of hardware

     i 147,674        i 57,841        i 240,074        i 296,278  

Total costs and other expenses

     i 476,604        i 393,783        i 1,902,989        i 1,455,177  

Gross profit

     i 1,340,504        i 979,766        i 4,926,815        i 3,806,658  
                                 

Operating Expenses

                               

Selling, general and administrative

     i 1,547,376        i 2,510,706        i 5,422,272        i 6,315,277  

Research, development and engineering

     i 558,686        i 829,506        i 1,807,026        i 2,418,855  

Total Operating Expenses

     i 2,106,062        i 3,340,212        i 7,229,298        i 8,734,132  

Operating loss

    ( i 765,558 )     ( i 2,360,446 )     ( i 2,302,483 )     ( i 4,927,474 )

Other income (expense)

                               

Interest income

     i 5,917        i 8        i 5,944        i 216  

Loss on foreign currency transactions

     i -        i -       ( i 15,000 )      i -  

Investment-debt security reserve

     i -       ( i 40,000 )      i -       ( i 190,000 )

Change in fair value of convertible note

     i 167,283        i -        i 264,706        i -  

Interest expense

    ( i 45,655 )     ( i 2,071 )     ( i 159,379 )     ( i 3,611 )

Total other income (expense), net

     i 127,545       ( i 42,063 )      i 96,271       ( i 193,395 )
                                 

Loss before provision for income tax

    ( i 638,013 )     ( i 2,402,509 )     ( i 2,206,212 )     ( i 5,120,869 )
                                 

Provision for (income tax) tax benefit

     i 189        i -       ( i 142,811 )      i -  
                                 

Net loss

  $ ( i 637,824 )   $ ( i 2,402,509 )   $ ( i 2,349,023 )   $ ( i 5,120,869 )
                                 

Comprehensive loss:

                               

Net loss

  $ ( i 637,824 )   $ ( i 2,402,509 )   $ ( i 2,349,023 )   $ ( i 5,120,869 )

Other comprehensive income (loss) – Foreign currency translation adjustment

     i 35,364       ( i 119,269 )      i 127,394       ( i 229,350 )

Comprehensive loss

  $ ( i 602,460 )   $ ( i 2,521,778 )   $ ( i 2,221,629 )   $ ( i 5,350,219 )
                                 

Basic and Diluted Loss per Common Share

  $ ( i 0.07 )   $ ( i 0.29 )   $ ( i 0.26 )   $ ( i 0.64 )
                                 

Weighted Average Common Shares Outstanding:

                               

Basic and diluted

     i 9,081,873        i 8,148,848        i 9,042,319        i 8,054,207  

 

See accompanying notes to the condensed consolidated financial statements. 

 

4

 

 

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY

(Unaudited)

 

                           

Accumulated

                 
                   

Additional

   

Other

                 
   

Common Stock

   

Paid-in

   

Comprehensive

   

Accumulated

         
         

Amount

               

Deficit

   

Total

 

Balance as of January 1, 2023

     i 9,190,504     $  i 919     $  i 122,028,612     $ ( i 242,602 )   $ ( i 116,485,373 )   $  i 5,301,556  

Issuance of common stock for directors’ fees

     i 15,388        i 1        i 12,001        i -        i -        i 12,002  

Issuance of common stock to employees

     i 40,000        i 4        i -        i -        i -        i 4  

Restricted stock forfeited

    ( i 19,834 )     ( i 2 )     ( i 3,103 )      i -        i -       ( i 3,105 )

Foreign currency translation adjustment

             i         i         i 72,146        i -        i 72,146  

Share-based compensation

    -        i -        i 62,474        i -        i -        i 62,474  

Net loss

    -        i -        i -        i -       ( i 288,322 )     ( i 288,322 )

Balance as of March 31, 2023

     i 9,226,058     $  i 922     $  i 122,099,984     $ ( i 170,456 )   $ ( i 116,773,695 )   $  i 5,156,755  

Issuance of common stock for directors’ fees

     i 23,150        i 2        i 16,000        i -        i -        i 16,002  

Issuance of restricted common stock to employees

     i         i -        i -        i -        i -        i -  

Restricted stock forfeited

    ( i 14,375 )     ( i 1 )      i 1        i -        i -        i -  

Issuance of common stock for Employee stock purchase plan

     i 28,020        i 3        i 13,931        i -        i -        i 13,934  

Share based compensation for employee stock plan

    -        i -        i 3,563        i -        i -        i 3,563  

Foreign currency translation adjustment

    -        i -        i -        i 19,884        i -        i 19,884  

Share-based compensation

    -        i -        i 57,831        i -        i -        i 57,831  

Net loss

    -        i -        i -        i -       ( i 1,422,878 )     ( i 1,422,878 )

Balance as of June 30, 2023

     i 9,262,853     $  i 926     $  i 122,191,310     $ ( i 150,572 )   $ ( i 118,196,573 )   $  i 3,845,091  

Issuance of common stock for directors’ fees

     i 16,874        i 2        i 11,000        i -        i -        i 11,002  

Restricted stock forfeited

    ( i 33,333 )     ( i 3 )      i -        i -        i -       ( i 3 )

Issuance of restricted common stock to employees and directors

     i 255,275        i 25       ( i 25 )      i -        i -        i -  

Share based compensation for employee stock plan

    -        i -        i 10,398        i -        i -        i 10,398  

Foreign currency translation adjustment

    -        i -        i -        i 35,364        i -        i 35,364  

Share-based compensation

    -        i -        i 50,423        i -        i -        i 50,423  

Net loss

    -        i -        i -        i -       ( i 637,824 )     ( i 637,824 )

Balance as of September 30, 2023

     i 9,501,669     $  i 950     $  i 122,263,106     $ ( i 115,208 )   $ ( i 118,834,397 )   $  i 3,314,451  

 

See accompanying notes to the condensed consolidated financial statements. 

 

5

 

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY

(Unaudited)

 

                           

Accumulated

                 
                   

Additional

   

Other

                 
   

Common Stock

   

Paid-in

   

Comprehensive

   

Accumulated

         
         

Amount

               

Deficit

   

Total

 

Balance as of January 1, 2022

     i 7,853,759     $  i 786     $  i 120,190,139     $  i -     $ ( i 104,575,470 )   $  i 15,615,455  

Issuance of common stock for directors’ fees

     i 9,382        i 1        i 22,019        i -        i -        i 22,020  

Issuance of common stock pursuant to Swivel purchase agreement

     i 269,060        i 27        i 599,977        i -        i -        i 600,004  

Issuance of restricted common stock to employees and directors

     i 274,250        i 27       ( i 27 )      i -        i -        i -  

Foreign currency translation adjustment

    -        i -        i -        i 55,802        i -        i 55,802  

Share-based compensation

    -        i -        i 87,677        i -        i -        i 87,677  

Net loss

    -        i -        i -        i -       ( i 999,403 )     ( i 999,403 )

Balance as of March 31, 2022

     i 8,406,451     $  i 841     $  i 120,899,785     $  i 55,802     $ ( i 105,574,873 )   $  i 15,381,555  

Issuance of common stock for directors’ fees

     i 9,117        i 1        i 18,005        i -        i -        i 18,006  

Issuance of restricted common stock to employees

     i 1,250        i -        i -        i -        i -        i -  

Restricted stock forfeited

    ( i 1,250 )      i -        i -        i -        i -        i -  

Issuance of common stock for Employee stock purchase plan

     i 26,006        i 2        i 39,123        i -        i -        i 39,125  

Share based compensation for employee stock plan

    -        i -        i 8,314        i -        i -        i 8,314  

Foreign currency translation adjustment

    -        i -        i -       ( i 165,883 )      i -       ( i 165,883 )

Share-based compensation

    -        i -        i 57,379        i -        i -        i 57,379  

Net loss

    -        i -        i -        i -       ( i 1,718,957 )     ( i 1,718,957 )

Balance as of June 30, 2022

     i 8,441,574     $  i 844     $  i 121,022,606     $ ( i 110,081 )   $ ( i 107,293,830 )   $  i 13,619,539  

Issuance of common stock for directors’ fees

     i 8,547        i 1        i 18,008        i -        i -        i 18,009  

Issuance of restricted common stock to employees

     i 2,500        i -        i -        i -        i -        i -  

Foreign currency translation adjustment

    -        i -        i -       ( i 119,269 )      i -       ( i 119,269 )

Share-based compensation

    -        i -        i 82,738        i -        i -        i 82,738  

Net loss

    -        i -        i -        i -       ( i 2,402,509 )     ( i 2,402,509 )

Balance as of September 30, 2022

     i 8,452,621     $  i 845     $  i 121,123,352     $ ( i 229,350 )   $ ( i 109,696,339 )   $  i 11,198,508  

 

See accompanying notes to the condensed consolidated financial statements.

 

6

 

 

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

  

Nine Months Ended September 30,

 
  

2023

  

2022

 
         

CASH FLOW FROM OPERATING ACTIVITIES:

        

Net loss

 $( i 2,349,023) $( i 5,120,869)

Adjustments to reconcile net loss to net cash used for operating activities:

        

Depreciation

   i 38,213    i 33,813 

Amortization of intangible assets

   i 217,978    i 216,806 

Amortization of capitalized contract costs

   i 126,057    i 80,019 

Operating leases right-of-use assets

   i 146,890    i 87,903 

Reserve for Investment – debt security

   i -    i 190,000 

Allowance for note receivable

   i     i 40,000 

Share and warrant-based compensation for employees and consultants

   i 163,584    i 236,108 

Stock based directors’ fees

   i 39,006    i 58,035 

Change in fair value of convertible note

  ( i 264,706)   i - 

Deferred income tax benefit

  ( i 20,000)   i - 

Bad debts

   i 150,000    i 130,111 

Change in assets and liabilities:

        

Accounts receivable

  ( i 1,334,989)  ( i 264,635)

Due from factor

  ( i 13,072)   i - 

Capitalized contract costs

  ( i 107,336)  ( i 120,968)

Inventory

   i 145,156    i 47,993 

Resalable software license rights

   i -    i 7,466 

Prepaid expenses and other

  ( i 51,831)  ( i 120,977)

Accounts payable

   i 488,416    i 239,227 

Accrued liabilities

   i 327,131   ( i 6,882)

Income taxes payable

   i 62,811    i - 

Deferred revenue

   i 128,253    i 43,351 

Operating lease liabilities

  ( i 154,460)  ( i 104,904)

Net cash used for operating activities

  ( i 2,261,922)  ( i 4,328,403)

CASH FLOWS FROM INVESTING ACTIVITIES:

        

Purchase of Swivel Secure, net of cash acquired of $729,905

   i -   ( i 543,578)

Receipt of cash from note receivable

   i -    i 9,000 

Capital expenditures

   i -   ( i 31,066)

Net cash used for investing activities

   i -   ( i 565,644)

CASH FLOW FROM FINANCING ACTIVITIES:

        

Deferred offering costs

  ( i 25,434)   i - 

Receipt of cash from Employee stock purchase plan

   i 13,934    i 39,125 

Repayment of government loan

  ( i 113,885)   i - 

Net cash provided by (used in) financing activities

  ( i 125,385)   i 39,125 
         

Effect of exchange rate changes

   i 58,871   ( i 124,507)
         

NET DECREASE IN CASH AND CASH EQUIVALENTS

  ( i 2,328,436)  ( i 4,979,429)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

   i 2,635,522    i 7,754,046 

CASH AND CASH EQUIVALENTS, END OF PERIOD

 $ i 307,086  $ i 2,774,617 

 

See accompanying notes to the condensed consolidated financial statements. 

 

7

 

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

 

SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION

 

   

Nine Months Ended September 30,

 
   

2023

   

2022

 
                 

Cash paid for:

               

Interest

  $  i 159,379     $  i 3,661  
                 

Noncash investing and financing activities

               

Accounts receivable acquired from Swivel Secure

  $  i -     $  i 702,886  

Equipment acquired from Swivel Secure

  $  i -     $  i 65,640  

Other assets acquired from Swivel Secure

  $  i -     $  i 20,708  

Intangible assets acquired from Swivel Secure

  $  i -     $  i 762,860  

Goodwill resulting from the acquisition from Swivel Secure

  $  i -     $  i 1,067,372  

Accounts payable and accrued expenses acquired from Swivel Secure

  $  i -     $  i 431,884  

Government loan acquired from Swivel Secure

  $  i -     $  i 544,000  

Common stock issued for acquisition of Swivel Secure

  $  i -     $  i 600,004  

Operating lease right-of-use asset and liability for new lease

  $  i -     $  i 105,893  

 

See accompanying notes to the condensed consolidated financial statements. 

 

8

 

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023 (Unaudited)

 

 

 

 
 i 

1.

NATURE OF BUSINESS AND BASIS OF PRESENTATION

 

Nature of Business

 

The Company, founded in 1993, develops and markets proprietary fingerprint identification biometric technology and software solutions enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally. The Company was a pioneer in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit cards, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.

 

 i 

Basis of Presentation

 

The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company” or “BIO-key”) and are stated in conformity with accounting principles generally accepted in the United States of America (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Intercompany accounts and transactions have been eliminated in consolidation.

 

In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company’s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at  December 31, 2022 was derived from the audited financial statements, but does not include all of the disclosures required by GAAP. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on June 1, 2023.

 

 i 

Foreign Currencies

 

The Company accounts for foreign currency transactions pursuant to ASC 830, Foreign Currency Matters ("ASC 830”). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. Revenues and expenses are translated using the average exchange rates prevailing throughout the respective periods. All transaction gains and losses from the measurement of monetary balance sheet items denominated in Euros are reflected in the statement of operations as appropriate. Translation adjustments are included in accumulated other comprehensive income (loss).

 

 i 

Recently Issued Accounting Pronouncements

 

Effective January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016-13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. The adoption of ASU 2016-13 did not have a material effect on the consolidated financial statements of the Company

 

9

 

In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entitys Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for the Company on January 1, 2024 and should be applied on a full or modified retrospective basis. The Company is currently assessing the impact ASU 2020-06 will have on its consolidated financial statements.

 

Management does not believe that any other recently issued, but not yet effective, accounting standard, if currently adopted, would have a material effect on the accompanying consolidated financial statements.

 

 / 
 
 i 

2.

GOING CONCERN

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has suffered substantial net losses and negative cash flows from operations in recent years and is dependent on debt and equity financing to fund its operations all of which raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to increase its revenue and meet its financing requirements on a continuing basis and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

 

As of the date of this report, the Company does not have enough cash for twelve months of operations. The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company's ability to continue as a going concern. In recent periods, the Company has reduced its marketing, research and development, and rent expenses. In addition, the Company has purchased inventory for projects in Nigeria, which have been delayed in deployment, and is currently exploring other markets and opportunities to sell or return the product to generate additional cash.

 

 
 i 

3.

REVENUE FROM CONTRACTS WITH CUSTOMERS

 

Disaggregation of Revenue

 

The following table summarizes revenue from contracts with customers for the three month periods ended September 30, 2023 and September 30, 2022:

 

 i 
  

North

              

September 30,

 
  

America

  

Africa

  

EMESA*

  

Asia

  

2023

 
                     

Services

 $ i 294,581  $ i 26,009  $ i 267,303  $ i -  $ i 587,893 

License fees

   i 426,059    i -    i 523,956    i -    i 950,015 

Hardware

   i 48,057    i -    i 231,143    i -    i 279,200 

Total Revenues

 $ i 768,697  $ i 26,009  $ i 1,022,402  $ i -  $ i 1,817,108 
 / 

 

  

North

              

September 30,

 
  

America

  

Africa

  

EMESA*

  

Asia

  

2022

 
                     

Services

 $ i 280,192  $ i 22,677  $ i 69,087  $-  $371,956 

License fees

   i 468,090    i -    i 450,170    i -   918,260 

Hardware

   i 48,226    i 13,800    i 11,412    i 9,895   83,333 

Total Revenues

 $ i 796,508  $ i 36,477  $ i 530,669  $9,895  $1,373,549 

 

10

 

The following table summarizes revenue from contracts with customers for the nine month periods ended September 30, 2023 and September 30, 2022:

 

  

North

              

September 30,

 
  

America

  

Africa

  

EMESA*

  

Asia

  

2023

 
                     

Services

 $ i 840,045  $ i 75,806  $ i 812,654  $ i 12,375  $ i 1,740,880 

License fees

   i 1,614,971    i 552,630    i 2,426,090    i 70,650    i 4,664,341 

Hardware

   i 134,390    i -    i 278,293    i 11,900    i 424,583 

Total Revenues

 $ i 2,589,406  $ i 628,436  $ i 3,517,037  $ i 94,925  $ i 6,829,804 

 

  

North

              

September 30,

 
  

America

  

Africa

  

EMESA*

  

Asia

  

2022

 
                     

Services

 $ i 936,910  $ i 60,629  $ i 205,274  $ i 53  $ i 1,202,866 

License fees

   i 1,436,704    i 517,161    i 1,507,051    i 79,676    i 3,540,592 

Hardware

   i 323,338    i 25,833    i 18,342    i 150,864    i 518,377 

Total Revenues

 $ i 2,696,952  $ i 603,623  $ i 1,730,667  $ i 230,593  $ i 5,261,835 

 

*EMESA – Europe, Middle East, South America

 

Deferred Revenue 

 

Deferred revenue includes customer advances and amounts that have been paid by customer for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is  i 12- i 60 months. Contracts greater than 12 months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At September 30, 2023 and December 31, 2022, amounts in deferred revenue were approximately $ i 642,000 and $ i 515,000, respectively. Revenue recognized during the three and nine-months ended September 30, 2023 from amounts included in deferred revenue at the beginning of the period was approximately $ i 67,000 and $ i 402,000, respectively. Revenue recognized during the three and nine-months ended September 30, 2022 from amounts included in deferred revenue at the beginning of the period was approximately $ i 62,000 and $ i 448,000, respectively. The Company did not recognize any revenue from performance obligations satisfied in prior periods.

 

 / 
 
 i 

4.

ACCOUNTS RECEIVABLE

 

Accounts receivable are carried at original amount less an estimate made for credit losses based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for credit losses by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, current economic conditions and other relevant factors, including specific reserves for certain accounts. Accounts receivable are written off when deemed uncollectible.

 

Accounts receivable at September 30, 2023 and December 31, 2022 consisted of the following: 

 

 i 
  

September 30,

  

December 31,

 
  

2023

  

2022

 
         

Accounts receivable

 $ i 3,423,003  $ i 2,096,569 

Allowance for credit losses

  ( i 623,785)  ( i 573,785)

Accounts receivable, net of allowances for credit losses

 $ i 2,799,218  $ i 1,522,784 
 / 

 

Bad debt expenses are recorded in selling, general, and administrative expense.

 

11

   / 
 
 i 

5.

SHARE BASED COMPENSATION

 

The following table presents share-based compensation expenses included in the Company’s unaudited condensed interim consolidated statements of operations:

 

 i 
  

Three Months Ended September 30,

 
  

2023

  

2022

 
         

Selling, general and administrative

 $ i 56,414  $ i 66,152 

Research, development and engineering

   i 15,406    i 17,547 
  $ i 71,820  $ i 83,699 
 / 

 

 

  

Nine Months Ended September 30,

 
  

2023

  

2022

 
         

Selling, general and administrative

 $ i 171,833  $ i 158,578 

Research, development and engineering

   i 48,758    i 34,818 
  $ i 220,591  $ i 193,396 

 

 / 
 
 i 

6.

INVENTORY

 

Inventory is stated at the lower of cost, determined on a first in, first out basis, or realizable value. The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. The Company also reserves for excess quantities, slow moving goods, and for other impairment of value based upon assumptions of future demand and market conditions. The $ i 400,000 reserve on inventory is due to slow moving inventory purchased for projects in Nigeria. The Company is exploring other markets and opportunities to sell or return the product. Inventory is comprised of the following as of:

 

 i 
  

September 30,

  

December 31,

 
  

2023

  

2022

 
         

Finished goods

 $ i 4,619,487  $ i 4,764,643 

Fabricated assemblies

   i 69,726    i 69,726 

Reserve on finished goods

  ( i 400,000)  ( i 400,000)

Total inventory

 $ i 4,289,213  $ i 4,434,369 
 / 

 

 / 
 
 i 

7.

COMMITMENTS AND CONTINGENCIES

 

Distribution Agreement

 

Swivel Secure has a distribution agreement with Swivel Secure Limited (“SSL”). Terms of the agreement include the following:

 

1.

The initial term of the agreement ends on January 31, 2027 and will be automatically extended for additional one-year terms thereafter unless either party provides written notice to the other party not later than 30 days before the end of the term that it does not wish to extend the term.

 

2.

SSL appoints Swivel Secure as the exclusive distributor of SSL’s products, to market, sell and distribute in the EMEA (Europe, Middle East and Africa), excluding the United Kingdom and Republic of Ireland, for a defined discount on the sale price.

 

3.

Swivel Secure is expected to generate a certain minimum level of orders of SSL products each year during the term of the agreement. If Swivel Secure fails to meet such minimum level of orders in any year, the exclusive distribution rights will terminate and Swivel Secure will serve as a non-exclusive distributer of SSL Products.

 

The Company expects the revenue targets to continue to be met based on historical performance and increasing distribution by Swivel Secure.

 

Litigation

 

From time to time, the Company may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of September 30, 2023, the Company was not a party to any pending lawsuits.

 

12

 
 
 i 

8.

LEASES

 

The Company’s leases office space in New Jersey, Minnesota, New Hampshire, Madrid and Hong-Kong with lease termination dates in 2023 and 2024. On August 11, 2023, the Company signed a new one-year lease starting September 1, 2023 for office space in New Jersey. The property leased in China is paid monthly as used, without a formal agreement. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases were:

 

 

 i 
  

3 Months ended

  

3 Months ended

 
  

September 30,

  

September 30,

 
  

2023

  

2022

 
         

Lease cost

        

Total lease cost

  

$ 34,145

   

$ 63,973

 

 

  

9 Months ended

  

9 Months ended

 
  

September 30,

  

September 30,

 
  

2023

  

2022

 
         

Lease cost

        

Total lease cost

 $ i 145,828  $ i 163,401 

 

  

September 30,

  

December 31,

 

Balance sheet information

 

2023

  

2022

 

Operating right-of-use assets

 $ i 50,465  $ i 197,355 
         

Operating lease liabilities, current portion

 $ i 51,746  $ i 159,665 

Operating lease liabilities, non-current portion

   i -    i 37,829 

Total operating lease liabilities

 $ i 51,746  $ i 197,494 
         

Weighted average remaining lease term (in years) – operating leases

   i 0.93    i 0.96 

Weighted average discount rate – operating leases

   i 5.50%   i 5.50%
         
         

Cash paid for amounts included in the measurement of operating lease liabilities for the nine months ended September 30, 2023 and 2022:

 $ i 197,946  $ i 144,985 

 

Maturities of operating lease liabilities were as follows as of September 30, 2023:

 

2023 (3 months remaining)

 $ i 14,553 

2024

   i 38,808 

Total future lease payments

 $ i 53,361 

Less: imputed interest

  ( i 1,615)

Total

 $ i 51,746 

 

 / 
 
 i 

9.

CONVERTIBLE NOTE PAYABLE

 

Securities Purchase Agreement dated December 22, 2022

 

On December 22, 2022, the Company entered into and closed a securities purchase agreement (the “Purchase Agreement”) and issued a $ i 2,200,000 principal amount senior secured promissory note (the “Note”). At closing, a total of $ i 2,002,000 was funded, with the proceeds to be used for general working capital.

 

The principal amount of the Note was due six months following the date of issuance, subject to one six-month extension by the Company. The Company elected to extend the due date to December 22, 2023. Interest under the Note accrued at a rate of  i 10% per annum through month six and accrues at a rate of  i 12% per annum in months seven through twelve, payable monthly. The Note is secured by a lien on substantially all of the Company’s assets and properties can be prepaid in whole or in part without penalty at any time.

 

In connection with the issuance of the Note, the Company issued to the investor  i 700,000 shares of Common Stock (the “Commitment Shares”) valued at $ i 1.00 per share and a warrant (the “Warrant”) to purchase  i 200,000 shares of common stock (the “Warrant Shares”) at an exercise price of $ i 3.00 per share, exercisable commencing on the date of issuance with a term of five years. 

 

13

 

Upon issuance, the Note was not convertible into common stock or any other securities of the Company. Only after a date that is six (6) months following the issuance date of the Note and upon the occurrence of any events of default (as defined) and expiration of any applicable cure periods, all amounts due under the Note will immediately and automatically become due and payable in full, interest will accrue at the higher of  i 18% per annum or the maximum amount permitted by applicable law, the outstanding principal amount due under the Note will be increased by  i 30%, and the Investor will have the right to convert all amounts due under the Note into shares of common stock (the “Conversion Shares”) at a conversion price equal to the 10 day volume weighted average sales price of the Company’s common stock on the date of conversion, subject to the Share Cap described in the paragraph below.

 

The aggregate number of shares of common stock issuable in the forgoing transaction consisting of the Commitment Shares, the Warrant Shares, and the Conversion Shares are capped at  i 1,684,576 which is  i 19.9% of the Company’s issued and outstanding shares of common stock on December 22, 2022, the date the definitive transaction documents were executed (the “Share Cap”).

 

The Company elected the fair value measurement option for the Note as the Note had embedded derivatives that required bifurcation and recorded the entire hybrid financing instrument at fair value under the guidance of ASC 825, Financial Instruments. As a result, the Note was recorded at fair value upon issuance and is subsequently remeasured at each reporting date until settled or converted. The Company reports interest expense, including accrued interest, related to the Note under the fair value option, separately from within the change in fair value of the Note in the accompanying consolidated statement of operations. See Note 13.

 

As of September 30, 2023 and December 31, 2022, the Note with principal balance of $ i 2,200,000, at fair value, was recorded at $ i 2,331,497 and $ i 2,596,203, respectively. See note 16.

 

 / 
 
 i 

10.

EARNINGS (LOSS) PER SHARE - COMMON STOCK (“EPS”)

 

The Company’s basic EPS is calculated using net income (loss) available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of preferred stock.

 

The following table sets forth options and warrants which were excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:

 

 i 
  

Three Months ended

  

Nine Months Ended

 
  

September 30,

  

September 30,

 
  

2023

  

2022

  

2023

  

2022

 
                 

Stock options

   i 166,234    i 203,257    i 166,234    i 203,257 

Warrants

   i 4,864,150    i 4,672,025    i 4,872,025    i 4,672,025 

Total

   i 5,030,384    i 4,875,282    i 5,038,259    i 4,875,282 
 / 

 

 / 
 
 i 

11.

STOCKHOLDERS’ EQUITY

 

Issuances of Common Stock

 

During the nine-month periods ended September 30, 2023, there have not been any shares of common stock issued to anyone outside the Company.

 

On June 18, 2021, the stockholders approved the Employee Stock Purchase Plan. Under the terms of this plan,  i 789,000 shares of common stock are reserved for issuance to employees and officers of the Company at a purchase price equal to  i 85% of the lower of the closing price of the common stock on the first day or the last day of the offering period as reported on the Nasdaq Capital Market. Eligible employees are granted an option to purchase shares under the plan funded by payroll deductions. The Board may suspend or terminate the plan at any time, otherwise the plan expires June 17, 2031. On September 30, 2023,  i 28,020 shares were issued to employees which resulted in a $ i 3,563 non-cash compensation expense for the Company. On September 30, 2022,  i 26,006 shares were issued to employees which resulted in a $ i 8,314 non-cash compensation expense for the Company.

 

On March 8, 2022, the Company issued  i 269,060 shares of common stock of which  i 89,687 shares were held back by the Company to secure certain indemnification obligations under the Swivel Secure stock purchase agreement. The shares of Company common stock were issued at a total cost of $ i 600,004, priced at $ i 2.23, based on the contractual 20 day volume-weighted average price of the Company’s common stock immediately prior to the payment date as reported on the Nasdaq Capital Market

 

Issuances of Restricted Stock

 

Restricted stock consists of shares of common stock that are subject to restrictions on transfer and risk of forfeiture until the fulfillment of specified conditions. The fair value of nonvested shares is determined based on the market price of the Company's common stock on the grant date. Nonvested stock is expensed ratably over the term of the restriction period.

 

During the nine-month periods ended September 30, 2023 and 2022, the Company issued  i 295,275 and  i 275,000 shares of restricted common stock, respectively, to certain employees and directors. These shares vest in equal annual installments over a three-year period from the date of grant and had a fair value on the date of issuance of $ i 170,974 and $ i 592,075, respectively.

 

14

 

During the nine-month periods ended September 30, 2023 and 2022,  i 67,542 and  i 1,250 shares of restricted common stock were forfeited, respectively.

 

Restricted stock compensation for the three-month periods ended September 30, 2023 and 2022, was $ i 50,422 and $ i 65,836, respectively.

 

Restricted stock compensation for the nine-month periods ended September 30, 2023 and 2022, was $ i 164,259 and $ i 156,880, respectively.

 

Issuances to Directors

 

During the three and nine-month periods ended September 30, 2023, the Company issued  i 16,874 and  i 55,4128 shares of common stock to its directors in lieu of payment of board and committee fees valued at $ i 11,002 and $ i 39,006, respectively. 

 

During the three and nine-month periods ended September 30, 2022, the Company issued  i 8,547 and  i 27,046 shares of common stock to its directors in lieu of payment of board and committee fees valued at $ i 18,009 and $ i 58,035, respectively. 

 

Employees exercise options

 

During the three and nine-month periods ended September 30, 2023 and 2022, no employee stock options were exercised.

 

3. Warrants

 

There were no warrants issued during the three and nine-month periods ended September 30, 2023 and 2022.  Subsequently, warrants were issued October 31, 2023 as part of the units' issue in the public offering.

 

 / 
 
 i 

12.

FAIR VALUES OF FINANCIAL INSTRUMENTS

 

Cash and cash equivalents, accounts receivable, due from factor, accounts payable and accrued liabilities are carried at, or approximate, fair value because of their short-term nature. The carrying value of the Company’s government loan payable approximates fair value as the interest rate related to the financial instruments approximated market.

 

 
 i 

13.

FAIR VALUE MEASUREMENT OF CONVERTIBLE NOTE PAYABLE

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

 

The following tables summarize the Note measured at fair value at September 30, 2023 and December 31, 2022:

 

 i 

September 30, 2023

 

Total

  

Level 1

  

Level 2

  

Level 3

 
                 

Convertible note at fair value

 $ i 2,331,497  $ i -  $ i -  $ i 2,331,497 
 / 

 

December 31, 2022

 

Total

  

Level 1

  

Level 2

  

Level 3

 
                 

Convertible note at fair value

 $ i 2,596,203  $ i -  $ i -  $ i 2,596,203 

 

15

 

The Company estimated the fair value of the convertible note using a probability-weighted discounted cash flow model with the following assumptions and significant terms of the Note at both September 30, 2023 and December 31, 2022:

 

1.

Face amount - $ i 2,200,000

 

 

2.

Nominal interest rate –  i 14.03% at September 30, 2023 and  i 10% at  December 31, 2022

 

 

3.

Default interest rate –  i 18%

 

 

4.

Increase in principal upon a default –  i 30%

 

 

5.

Present value discount rate –  i 14.03% at September 30, 2023, and  i 15.18% at December 31, 2022

 

 

6.

Likelihood of default – estimated to be between  i 50% at the extended maturity date

 

The following table shows the changes in fair value measurements for the convertible note using significant unobservable inputs (Level 3) during the three months ended September 30, 2023:

 

 i 

Beginning balance

 $ i 2,596,203 

Purchases and issuances

   i - 

Change in fair value for the three months ended March 31, 2023

  ( i 141,991)

Balance at March 31, 2023

 $ i 2,454,212 

Change in fair value for the three months ended June 30, 2023

   i 44,568 

Balance at June 30, 2023

 $ i 2,498,780 

Change in fair value for the three months ended September 30, 2023

  ( i 167,283)

Ending balance at September 30, 2023

 $ i 2,331,497 
 / 

 

 / 
 
 i 

14.

MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE

 

During each of the three month periods ended September 30, 2023, and 2022,  i two customers accounted for  i 33% and one customer accounted for  i 16% of the revenue, respectively. For the nine month periods ended September 30, 2023, and 2022,  i two customers accounted for  i 23% and one customer accounted for  i 11% of revenue, respectively.

 

Three customers accounted for  i 77% of current accounts receivable at September 30, 2023. At December 31, 2022, one customer accounted for  i 35% of current accounts receivable.

 

 / 
 
 i 

15.

INCOME TAXES

 

United States, Hong Kong and Nigeria

The Company recorded  i no income tax expense for the three and nine months ended September 30, 2023 and 2022 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.

 

As of September 30, 2023 and December 31, 2022, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

 

Spain

The provision for income taxes amounted to $ i 142,811.  Current income taxes totaled $ i 162,811 and deferred tax benefit totaled $ i 20,000.  The deferred tax liability presented on the condensed consolidated balance sheet relates to intangible assets from the acquisition of Swivel Secure.

 

 / 
 
 i 

16

SUBSEQUENT EVENTS

 

On October 30, 2023, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors in connection with a public offering of the Company’s securities (the “Offering”). At the closing of Offering on October 31, 2023, the Company issued and sold  i 21,430,000 units (the “Units”), consisting of  i 4,230,000 share of common stock, par value $ i 0.0001 per share (the “Common Stock”),  i 17,200,000 pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”), and  i 21,430,000 warrants to purchase share of Common Stock (the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants”). Each Unit was sold at a public offering price of $ i 0.175. The Common Warrants are immediately exercisable at an exercise price of $ i 0.175 per share and expire on the five-year anniversary of the date of issuance. The Pre-Funded Warrants are immediately exercisable at an exercise price of $ i 0.001 per share. The Offering was made pursuant to the Company’s Registration Statement on Form S-1. The net proceeds from the offering were approximately $ i 3.3 million, after deducting the placement agent fees and offering expenses. The Company used $ i 1,400,000 of the net proceeds to partially repay outstanding indebtedness due under the Note and the balance is being used for general corporate and working capital purposes.

 

The Company is not currently in compliance with the continued listing requirement of the Nasdaq Stock Market to maintain a minimum bid price of $1.00 per share.  If the Company does not regain compliance by January 8, 2024, it will be subject to immediate delisting from Nasdaq. On November 14, 2023, the Company filed a Preliminary Proxy Statement with the SEC to solicit stockholder approval of a reverse stock split in an effort to regain compliance with the minimum bid requirement.  The Preliminary Proxy Statement also seeks stockholder approval of the BIO-key International, Inc. 2023 Stock Incentive Plan.

 

The Company has reviewed subsequent events through the date of this filing. 

 

16

   / 
 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

 

All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “should,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generally identify forward-looking statements. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy debt repayment obligations and working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency and exchange rates; the duration and extent of continued hostilities in Ukraine and its impact on our European customers; delays in the development of products, statements of assumption underlying any of the foregoing, and numerous other matters of national, regional and global scale, including those set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and other filings with the Securities and Exchange Commission (“SEC”). These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, presently or in the future. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS 

 

This Managements Discussion and Analysis of Financial Condition and Results of Operations is provided as a supplement to and should be read in conjunction with our unaudited condensed consolidated financial statements and related information contained herein and our audited financial statements as of December 31, 2022.

 

Overview

 

BIO-key International, Inc. (the “Company,” “BIO-key,” “we,” or “us”) is a leading identity and access management, or IAM, platform provider enabling secure work-from-anywhere for enterprise, education, and government customers. Our vision is to enable any organization to secure streamlined and passwordless workforce, employee, customer, student and citizen access to any online service, workstation, or mobile application, without a requirement to use tokens or phones. Our products include PortalGuard® and PortalGuard Identity-as-a-Service (IDaaS) enterprise IAM, AuthControl Sentry, AuthControl Enterprise, AuthControl MSP, WEB-key® biometric civil and large-scale ID infrastructure, and accessory hardware to provide a complete solution for our customers.

 

Millions of people use BIO-key multi-factor-authentication, or MFA, solutions every day to securely access a variety of cloud, mobile and web applications, on-premise and cloud-based servers from all of their devices. We go beyond passwordless to offer phone-less and token-less authentication methods. This critical differentiator is particularly effective for retail, call center, manufacturing, shop-floor, and healthcare environments which utilize roving workers and shared workstations. Unlike most digital identity solutions, BIO-key also plays a role in securing in-person identity. For example, a banking customer has enrolled over 22 million of its customers’ biometrics with BIO-key as part of their know your customer, or KYC process, and then uses BIO-key fingerprint technology each time their customers access bank services to ensure positive identification before transacting with them.

 

BIO-key PortalGuard and hosted PortalGuard IDaaS authentication platforms enable our customers to assure that only the right people can access the right systems by utilizing our world-class biometric capabilities, among 17 other available authentication methods. PortalGuard goes beyond traditional MFA solutions by allowing roving users to biometrically authenticate at any workstation without using their phones or tokens which addresses sizeable security gaps, including eliminating unauthorized account delegation, detecting duplicate users, and accommodating in-person identification. 

 

Our customers use PortalGuard to manage and secure digital systems access by their employees, contractors and partners, which we call workforce identity. PortalGuard is also used to manage and secure the identities of an organization’s customers through integration of APIs we have developed and industry-standard federation standards, which we call customer identity. By using PortalGuard, our customers can securely collaborate with their supply chain and partners, and provide their customers with flexible, resilient user experiences online or in-person.

 

In 2022, we expanded our product offerings and customer base when we acquired Swivel Secure Europe, a Madrid, Spain based provider of IAM solutions. Swivel Secure Europe is the exclusive distributer of the AuthControl Sentry, AuthControl Enterprise, and AuthControl MSP product line in Europe, Africa and the Middle East, or EMEA, excluding the United Kingdom and Ireland. These solutions include PINsafe, a patented one-time-code extraction technology, helping enterprises manage the increasing data security risks posed by cloud services and “bring your own device” policies.

 

Large-scale customer and civil ID customers use our scalable biometric management platform and FBI-certified scanner hardware to manage enrollment, de-duplication and authentication for millions of users. 

 

We sell our branded USB fingerprint and FIDO authentication hardware as accessories to our IAM platforms, so that customers can have a single vendor providing all components of their IAM solution. Our fingerprint biometric platform is certified by NIST and unique among fingerprint platforms in that it supports mixing and matching of different manufactures’ fingerprint scanners in a deployment. This provides our customers with the flexibility to select the right scanner for their specific use case, without mandating the use of a particular scanner.

 

 

17

 

 

We operate a SaaS business model with customers subscribing to term use of our software for annual recurring revenue. We sell our products directly through our field and inside sales teams, as well as indirectly through our network of channel partners including resellers, system integrators, master agents and other distribution partners. Our subscription fees include a term license of hosted or on-premise product and technical support and maintenance of our platform. We base subscription fees primarily on the products used and the number of users enrolled in our platform. We generate subscription fees pursuant to noncancelable contracts with a weighted average duration of approximately one year.

 

Strategic Outlook

 

Historically, our largest market has been authentication within highly regulated industries such as government, financial services, and healthcare. With the adoption of MFA as a cybersecurity requirement, nearly all enterprises are beginning to adopt MFA for their user bases. Our ability to add value to or replace the first-generation MFA solutions deployed by these enterprises with our phone-less and token-less biometrics sets us apart from a crowded field of phone- and token-based MFA solutions. We believe that as enterprises experience the lifecycle costs associated with managing tokens and passwords, they will have an economic incentivize to consider adding BIO-key PortalGuard to their IAM solution. PortalGuard will allow them to continue to use their existing FIDO devices, while selectively augmenting their authentication options with tokenless and phoneless biometric choices.

 

We expect to grow our business within government services and highly-regulated industries in which we have historically had a strong presence including financial services, higher education, and healthcare.  We believe that continued heightened security and privacy requirements in these industries, and as colleges and universities continue operating in remote environments, we will generate increased demand for security solutions, including biometrics. In addition, we expect that the compatible, yet superior portable biometric user experience offered by our technology for Windows 10 users will accelerate the demand for our computer network log-on solutions and fingerprint readers.  Through value add-offerings via direct sales, resellers, and strategic partnerships with leading higher education platform providers, we will continue to grow our installed base.Through Swivel Secure Europe, we also expect to grow our business in EMEA.

 

Our primary sales strategies are focused on (i) increased marketing efforts into the IAM market, (ii) dedicated pursuit of large-scale identification projects across the globe and (iii) growing our channel alliance program which we have grown to more than one hundred and fifty participants and continues to generate incremental revenues.

 

A second component of our growth strategy is to pursue strategic acquisitions of select businesses and assets in the IAM space.  In furtherance of this strategy, we are active in the industry and regularly evaluate businesses that we believe will either provide an entry into new market verticals or be synergistic with our existing operations and in either case, be accretive to earnings.  We cannot provide any assurance as to whether we will be able to complete any acquisition and if completed, successfully integrate any business we acquire into our operations.

 

Critical Accounting Policies and Estimates

 

For detailed information regarding our critical accounting policies and estimates, see our financial statements and notes thereto included in this Report and in our Annual Report on Form 10-K for the year ended December 31, 2022.  There have been no material changes to our critical accounting policies and estimates from those disclosed in our most recent Annual Report on Form 10-K.

 

Recent Accounting Pronouncements

 

For detailed information regarding recent account pronouncements, see Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

 

18

 

RESULTS OF OPERATIONS

 

THREE MONTHS ENDED September 30, 2023 AS COMPARED TO September 30, 2022

 

Consolidated Results of Operations - Percent Trend

 

   

Three Months Ended September 30,

 
   

2023

   

2022

 

Revenues

               

Services

    32 %     27 %

License fees

    52 %     67 %

Hardware

    16 %     6 %

Total Revenues

    100 %     100 %

Costs and other expenses

               

Cost of services

    7 %     12 %

Cost of license fees

    11 %     13 %

Cost of hardware

    8 %     4 %

Total Cost of Goods Sold

    26 %     29 %

Gross profit

    74 %     71 %
                 

Operating expenses

               

Selling, general and administrative

    85 %     183 %

Research, development and engineering

    31 %     60 %

Total Operating Expenses

    116 %     243 %

Operating loss

    -42 %     -172 %
                 

Other expense

    7 %     -3 %

Loss before provision for income tax

    -35 %     -175 %

Provision for income tax

    0 %     0 %

Net loss

    -35 %     -175 %

 

19

 

Revenues and cost of goods sold

 

   

Three Months Ended

                 
   

September 30,

                 
   

2023

   

2022

   

$ Change

   

% Change

 
                                 

Revenues

                               

Service

  $ 587,893     $ 371,956     $ 215,937       58 %

License

    950,015       918,260       31,755       3 %

Hardware

    279,200       83,333       195,867       235 %

Total Revenue

  $ 1,817,108     $ 1,373,549     $ 443,559       32 %

 

   

Three Months Ended

                 
   

September 30,

                 
   

2023

   

2022

   

$ Change

   

% Change

 

Cost of Goods Sold

                               

Service

  $ 125,039     $ 162,632     $ (37,593 )     -23 %

License

    203,891       173,310       30,581       18 %

Hardware

    147,674       57,841       89,833       155 %

Total COGS

  $ 476,604     $ 393,783     $ 82,821       21 %

 

Revenues

 

For the three months ended September 30, 2023, and 2022, service revenues included approximately $297,000 and $304,000, respectively, of recurring maintenance and support revenue, and approximately $291,000 and $68,000 respectively, of non-recurring custom services revenue.  Recurring service revenue decreased $7,000 or 2% in 2023 which was due to the timing of certain quarter end renewals. Non-recurring custom services increased 326% due to additional new customer customizations and upgrades. As our customer base continues to grow, we expect the service revenue to increase in future periods.

 

For the three months ended September 30, 2023, license revenue increased $31,755 or 3% to $950,015 from $918,260 in the corresponding period in 2022. We increased both the variation and number of customers, including additional revenue from Swivel Secure customers and customers in the higher education market. 

 

For the three months ended  September 30, 2023, hardware sales increased 235% to $279,200 from $83,333 in the corresponding period in  2022. The increase was due largely to add-on orders from an existing customer in  2023, compared to reduced new hardware deployments in  2022
.

Costs of goods sold

 

For the three months ended September 30, 2023, cost of service decreased approximately $38,000 or 23% to $125,039 from $162,632 in the three months ended September 30, 2022, due to reduced costs to support the PortalGuard and new Swivel Secure deployments. For the three months ended September 30, 2023, license fees increased to $203,891 from $173,310 in the three months ended September 30, 2022, due largely to an increase in license fees for third-party software included in our Swivel Secure offerings. For the three months ended September 30, 2023, hardware costs increased to $147,674 from $57,841 in the three months ended September 30, 2022, related to costs associated with increased hardware revenue.

 

Selling, general and administrative

 

   

Three Months Ended

                 
   

September 30,

                 
   

2023

   

2022

   

$ Change

   

% Change

 
                                 

Selling, general and administrative

  $ 1,547,376     $ 2,510,706     $ (963,330 )     -38 %

 

Selling, general and administrative expenses for the three months ended September 30, 2023, decreased 38% from the corresponding period in 2022. The decreases included reductions in administration, sales and marketing personnel costs and marketing shows and expenses.

 

20

 

Research, development and engineering

 

   

Three Months Ended

                 
   

September 30,

                 
   

2023

   

2022

   

$ Change

   

% Change

 
                                 

Research, development, and engineering

  $ 558,686     $ 829,506     $ (270,820 )     -33 %

 

For the three months ended September 30, 2023, research, development, and engineering costs decreased 33% to $558,686 as compared to $829,506 in the corresponding period in 2022. The decrease consisted primarily of reductions in personnel costs and reductions in outside services related to the development of our MobileAuth application which we completed in 2022.

 

Other income (expense)

 

   

Three Months Ended

                 
   

September 30,

                 
   

2023

   

2022

   

$ Change

   

% Change

 
                                 

Interest income

  $ 5,917     $ 8     $ 5,909       73863 %

Investment-debt security reserve

    -       (40,000 )     40,000       100 %

Change in fair value of convertible note

    167,283       -       167,283       100 %

Interest expense

    (45,655 )     (2,071 )     (43,584 )     -2104 %

Other income (expense)

  $ 127,545     $ (42,063 )   $ 169,608       403 %

 

 

Other income (expense) for the three months ended  September 30, 2023 consisted of interest income of $5,917, interest expense of $45,655 on the secured note payable and the government loan through the BBVA bank net of interest and change in fair value of $167,283 on the convertible note payable. Other income(expense) for the three months ended  September 30, 2022 consisted of interest income of $8, a reserve on the investment-debt security as adjustment for collections in the amount of $40,000, and interest expense of $2,071 on the government loan through the BBVA bank.

 

   

Three Months Ended

                 
   

September 30,

                 
   

2023

   

2022

   

$ Change

   

% Change

 
                                 

Provision for income tax

  $ 189     $ -     $ 189       -100 %

 

The provision for income taxes for the three months ended September 30, 2023 consisted of current income taxes of $6,811 for our Swivel Secure subsidiary, and deferred tax benefit of $7,000 relating to intangible assets from the acquisition of Swivel Secure.

 

nine months ended September 30, 2023 AS COMPARED TO September 30, 2022

 

Consolidated Results of Operations -Percent Trend

 

   

Nine Months Ended September 30,

 
   

2023

   

2022

 

Revenues

               

Services

    25 %     23 %

License fees

    68 %     67 %

Hardware

    7 %     10 %

Total Revenues

    100 %     100 %

Costs and other expenses

               

Cost of services

    9 %     11 %

Cost of license fees

    15 %     11 %

Cost of hardware

    4 %     6 %

Total Cost of Goods Sold

    28 %     28 %

Gross profit

    72 %     72 %
                 

Operating expenses

               

Selling, general and administrative

    79 %     120 %

Research, development and engineering

    26 %     46 %

Total Operating Expenses

    105 %     166 %

Operating loss

    -33 %     -94 %
                 

Other expense

    1 %     -4 %

Loss before provision for income tax

    -32 %     -97 %

Provision for income tax

    -2 %     0 %
                 

Net loss

    -34 %     -97 %

 

21

 

Revenues and cost of goods sold

 

   

Nine Months Ended

                 
   

September 30,

                 
   

2023

   

2022

   

$ Change

   

% Change

 

Revenues

                               

Service

  $ 1,740,880     $ 1,202,866     $ 538,014       45 %

License

    4,664,341       3,540,592       1,123,749       32 %

Hardware

    424,583       518,377       (93,794 )     -18 %

Total Revenue

  $ 6,829,804     $ 5,261,835     $ 1,567,969       30 %
                                 

Cost of Goods Sold

                               

Service

    639,996       554,222       85,774       15 %

License

    1,022,919       604,677       418,242       69 %

Hardware

    240,074       296,278       (56,204 )     -19 %

Total COGS

  $ 1,902,989     $ 1,455,177     $ 447,812       31 %

 

Revenues

 

For the nine months ended September 30, 2023, and 2022, service revenues included approximately $899,000 and $944,000, respectively, of recurring maintenance and support revenue, and approximately $842,000 and $259,000, respectively, of non-recurring custom services revenue.  Recurring service revenue decreased 5% in the first nine months of 2023 due to the timing of certain quarter end renewals. Non-recurring custom services revenue increased 225% in the first nine months of 2023 due largely to the additional service revenue from Swivel Secure customers during the entire period in 2023. As our customer base continues to grow, we expect the service revenue to increase in future periods.

 

For the nine months ended September 30, 2023, license revenue increased 32% to $4,664,341 from $3,540,592 in the corresponding period in 2022. We increased both the variation and number of customers, including additional revenue from the Swivel Secure customers, and customers in the higher education market.

 

Hardware sales decreased $93,794 during the nine months ended September 30, 2023, to $424,583 from $518,377 in the nine months ended September 30, 2022. The decrease was attributable largely to the absence of any new large deployments in 2023, as compared a large order for our Pocket 10 product from a new customer in 2022.

 

Costs of goods sold

 

For the nine months ended September 30, 2023, cost of service increased $85,774 or 46% from $554,222 in the nine months ended September 30, 2022, due to the increased costs to support the new Swivel Secure deployments. For the nine months ended September 30, 2023, license fees increased to $1,022,919 from $604,677 in the nine months ended September 30, 2022, due largely to an increase in revenue and third-party software for the Swivel Secure licenses. For the nine months ended September 30, 2023, hardware costs decreased to $240,074 from $296,278 during the nine months ended September 30, 2022, corresponding to decreased hardware revenue.

 

Selling, general and administrative

 

   

Nine Months Ended

                 
   

September 30,

                 
   

2023

   

2022

   

$ Change

   

% Change

 
                                 

Selling, general and administrative

  $ 5,422,272     $ 6,315,277     $ (893,005 )     -14 %

 

Selling, general and administrative expenses for the nine months ended September 30, 2023, decreased 14% from the corresponding period in 2022. The decreases included reductions in administration, sales and marketing personnel costs and marketing shows and expenses.

 

Research, development and engineering

 

   

Nine Months Ended

                 
   

September 30,

                 
   

2023

   

2022

   

$ Change

   

% Change

 
                                 

Research, development and engineering

  $ 1,807,026     $ 2,418,855     $ (611,829 )     -25 %

 

For the nine months ended September 30, 2023, research, development and engineering costs decreased 25% from $2,418,855 to $1,807,026. The decrease consisted primarily of reductions in personnel costs and in outside services related to the development of our MobileAuth application which was completed in 2022.

 

22

 

Other income (expense)

 

   

Nine Months Ended

                 
   

September 30,

                 
   

2023

   

2022

   

$ Change

   

% Change

 
                                 

Interest income

  $ 5,944     $ 216     $ 5,728       2652 %

Loss on foreign currency transactions

    (15,000 )     -       (15,000 )     -100 %

Investment-debt security reserve

    -       (190,000 )     190,000       100 %

Change in fair value of convertible note

    264,706       -       264,706       -100 %

Interest expense

    (159,379 )     (3,611 )     (155,768 )     -4314 %

Other income (expense)

  $ 96,271     $ (193,395 )   $ 289,666       150 %

 

Other income (expense) for the nine  month period ended September 30, 2023 consisted of interest income of $5,944, a loss on foreign currency of $15,000, a change in fair value of $264,706 on the convertible note payable, and interest expense of $159,379 on the secured note payable and the government loan through the BBVA bank. Other income (expense) for the nine months ended September 30, 2022 consisted of interest income of $216, a reserve on the investment-debt security as adjustment for collections of such security of $190,000, and interest expense of $3,611 on the government loan through the BBVA bank.

 

Provision for income tax

 

   

Nine Months Ended

                 
   

September 30,

                 
   

2023

   

2022

   

$ Change

   

% Change

 
                                 

Provision for income tax

  $ (142,811 )   $ -     $ (142,811 )     -100 %

 

The provision for income taxes for the six months ended September 30, 2023 consisted of current income taxes of $162,811 for our Swivel Secure subsidiary, and deferred tax benefit of $20,000 relating to intangible assets from the acquisition of Swivel Secure.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Cash Flows

 

Operating activities overview

 

Net cash used by operations during the nine months ended September 30, 2023 was $2,326,417. Items of note included:

 

Net positive cash flows related to adjustments for non-cash expenses of approximately $622,000. 

 

Net positive cash flows related to inventory, accounts payable, accrued liabilities, income tax payable and deferred revenue of approximately $1,080,000. 

 

Negative cash flows related to changes in accounts receivable, due from factor and prepaid expenses of approximately $1,730,000, due to working capital management.

 

Financing activities overview

 

Net cash used for financing during the nine months ended September 30, 2023 was $125,386 for repayment of the government loan through the BBVA bank and $25,434 for deferred offering costs. Net cash received from financing during the nine months ended September 30, 2023  was $13,934 of proceeds from sales of common stock under the employee stock purchase plan.

 

Investing activities overview

 

There were no investing activities during the nine months ended September 30, 2023.

 

Liquidity and Capital Resources

 

Since our inception, our capital needs have been met through proceeds from the sale of equity and debt securities, and revenue. We expect capital expenditures to be less than $100,000 during the next twelve months.  

 

The following sets forth our investment sources of capital during the previous two years:

 

On October 30, 2023, we completed a public offering of units consisting of shares of common stock, pre-funded warrants to purchase shares of common stock, and warrants to purchase share of common stock.  Each Unit was sold at a public offering price of $0.175. resulting in net proceeds of $3.3 million, after deducting the placement agent fees and offering expenses.

 

In December 2022, we entered into and closed a securities purchase agreement (the “Purchase Agreement”) with AJB Capital Investments, LLC under which we issued a $2,200,000 principal amount senior secured promissory note (the “Note”). The principal amount of the Note was due six months following the date of issuance, subject to one six-month extension. We elected to extend the maturity date of the note to December 22, 2023. Interest under the Note accrued at a rate of 10% per annum, payable monthly through month six and currently accrues at the rate of 12% per annum in months seven through twelve, payable monthly. The Note is secured by a lien on substantially all of our assets and properties and can be prepaid in whole or in part without penalty at any time. We recently prepaid $1,400,000 of the principal amount due under the Note from the proceeds of the public offering.

23

 

In March 2022, in connection with the acquisition of Swivel Secure, we assumed a €500,000 government loan that was issued through BBVA Bank during the COVID-19 pandemic.  The loan bears interest at the rate of 1.75% per annum and is payable in monthly installments of approximately $11,900 inclusive of interest from May 2022 through maturity in April 2026. Upon closing of the acquisition, Swivel Secure had cash equal to the outstanding balance.

 

We entered into an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has been extended to October 31, 2023 and may be discontinued at that time. Pursuant to the terms of the arrangement, from time to time, we sell to the Factor a minimum of $150,000 per quarter of certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to us (the “Advance Amount”), with the remaining balance, less fees, forwarded to us once the Factor collects the full accounts receivable balance from the customer. In addition, from time to time, we receive over advances from the Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored and are determined by the number of days required for collection of the invoice. We expect to continue to use this factoring arrangement periodically to assist with our general working capital requirements due to contractual requirements.

 

 

Liquidity outlook

 

At September 30, 2023, our total cash and cash equivalents were $307,086, as compared to $2,635,522 at December 31, 2022.  At September 30, 2023, we had working capital of approximately $1,792,000. 

 

As discussed above, we have historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. We currently require approximately $710,000 per month to conduct our operations, a monthly amount that we have been unable to consistently achieve through revenue generation.  During for the first nine months of 2023, we generated $6,829,804 of revenue, which did not generate enough cash to fully fund our average monthly requirements. We expect that Swivel Secure will generate positive cash flow in 2023. We also have approximately $3.8 million of inventory purchased for projects in Nigeria. We are exploring other markets and opportunities to sell or return the product to generate additional cash.

 

If we are unable to generate sufficient revenue to fund current operations and execute our business plan, we may need to obtain additional third-party financing. The approximate $800,000 outstanding balance of the Note is due on December 22, 2023.  Unless we generate sufficient positive cash flow from operations or liquidation of existing inventory, we expect that we will need to obtain additional financing during the next twelve months to repay our outstanding secured note and support operations.

 

Our long-term viability and growth will depend upon the successful commercialization of our technologies and our ability to obtain adequate financing. To the extent that we require such additional financing, no assurance can be given that any form of additional financing will be available on terms acceptable to us, that adequate financing will be obtained to meet our needs, or that such financing would not be dilutive to existing stockholders. If available financing is insufficient or unavailable or we fail to continue to generate sufficient revenue, we may be required to further reduce operating expenses, delay the expansion of operations, be unable to pursue merger or acquisition candidates, or in the extreme case, not continue as a going concern.

 

ITEM 4.  CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of September 30, 2023, our CEO and CFO concluded that, as of such date, our disclosure controls and procedures were not effective to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As reported in our 10-K for the year ended December 31, 2022, in connection with the audit of our financial statements as of and for the year ended December 31, 2022, our management identified a material weakness relating to the effectiveness of management’s review and controls over the income tax provision in our financial footnotes, such that management’s review procedures were not operating at a level of precision to prevent or detect a potential material misstatement in our consolidated financial statements. We have also identified a lack of control over our foreign subsidiaries with respect to the filing of required tax returns on a timely basis. We are continuing to assess the actions that need to be taken to remedy each of these material weaknesses. Each of the material weaknesses noted will only be deemed to have been remediated after the new controls and procedures have been in place for a sufficient period and management has concluded through appropriate testing that the controls are operating effectively. We are in the process of implementing new controls designed to remediate the aforementioned material weaknesses. These efforts have included engaging a consultant to review income tax transactions for appropriate accounting treatment and assist with the preparation of financial statements.

 

Changes in Internal Control Over Financial Reporting

 

Other than the forgoing described above, there have been no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

24

 

ITEM 6. EXHIBITS

 

Exhibit

No.

 

Description

     
     

31.1

 

Certificate of CEO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended

     

31.2

 

Certificate of CFO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended

     

32.1

 

Certificate of CEO of Registrant required under 18 U.S.C. Section 1350

     

32.2

 

Certificate of CFO of Registrant required under 18 U.S.C. Section 1350

     

101.INS

 

Inline XBRL Instance

     

101.SCH

 

Inline XBRL Taxonomy Extension Schema

     

101.CAL

 

Inline XBRL Taxonomy Extension Calculation

     

101.DEF

 

Inline XBRL Taxonomy Extension Definition

     

101.LAB

 

Inline XBRL Taxonomy Extension Labels

     

101.PRE

 

Inline XBRL Taxonomy Extension Presentation

     

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

25

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

   

BIO-Key International, Inc.

     

Dated: November 20, 2023

 

/s/ Michael W. DePasquale

   

Michael W. DePasquale

   

Chief Executive Officer

   

(Principal Executive Officer)

     

Dated: November 20, 2023

 

/s/ Cecilia C. Welch

   

Cecilia C. Welch

   

Chief Financial Officer

   

(Principal Financial Officer)

 

 

26

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
6/17/31
1/31/27
1/8/24
1/1/24
12/31/23
12/22/23
Filed on:11/20/23
11/17/23
11/14/23PRE 14A
10/31/23424B4,  EFFECT
10/30/234,  8-K,  EFFECT
For Period end:9/30/23NT 10-Q
9/1/23
8/11/23
6/30/2310-Q,  4,  NT 10-Q
6/1/2310-K
3/31/2310-Q,  8-K,  NT 10-K,  NT 10-Q
1/1/23
12/31/2210-K,  NT 10-K
12/22/228-K
9/30/2210-Q
6/30/2210-Q,  4,  NT 10-Q
3/31/2210-K,  10-Q,  NT 10-K,  NT 10-Q
3/8/22
1/1/22
6/18/218-K,  DEF 14A
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/16/24  Bio Key International Inc.        424B3                  1:166K                                   RDG Filings/FA
 1/30/24  Bio Key International Inc.        S-1                    5:346K                                   RDG Filings/FA
Top
Filing Submission 0001437749-23-032644   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Apr. 28, 11:27:40.1am ET